Evidence map›Paper›PMID 38398552›Full record

ArticleMolecules (Basel, Switzerland)2024

Synthesis and Preclinical Evaluation of Two Novel

Arsyangela Verena, Helen Merkens, Chao-Cheng Chen, Devon E Chapple, Lei Wang, Shreya Bendre, Antonio A W L Wong, François Bénard, Kuo-Shyan Lin

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Dual targeting PET tracer [Theranostics · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Arsyangela VerenaDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z1L3, Canada.
Helen MerkensDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z1L3, Canada.
Chao-Cheng ChenDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z1L3, Canada.
Devon E ChappleDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z1L3, Canada.
Lei WangDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z1L3, Canada.
Shreya BendreDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z1L3, Canada.
Antonio A W L WongDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z1L3, Canada.ORCID 0000-0003-4617-9248
François BénardDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z1L3, Canada.ORCID 0000-0001-7995-3581
Kuo-Shyan LinDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z1L3, Canada.ORCID 0000-0002-0739-0780
University of British Columbia · CA

Funding

CIHR PJT-162243, PJT-180299 and PJT-180300
6 · The paper itself

Abstract

Some bispecific radiotracers have been developed to overcome the limitations of monospecific tracers and improve detection sensitivity for heterogeneous tumor lesions. Here, we aim to synthesize two bispecific tracers targeting prostate-specific membrane antigen (PSMA) and fibroblast activation protein (FAP), which are key markers expressed in prostate cancer. A pyridine-based FAP-targeted ligand was synthesized through multi-step organic synthesis and then connected to the 2-Nal-containing PSMA-targeted motif. The K

Indexed as

Gallium RadioisotopesProstatic NeoplasmsCell Line, TumorHEK293 CellsHumansMalePharmacophorePositron-Emission TomographyPyridinesRadiopharmaceuticalsGallium RadioisotopesPyridinesRadiopharmaceuticalsbispecific radiotracersFAPgallium-68PET/CTprostate cancerPSMA

Identifiers

PMID38398552
PMCPMC10892057
OpenAlexW4391683344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.